Johnson & Johnson Cash Flow from Operating Activities 2010-2024 | JNJ

Johnson & Johnson annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
  • Johnson & Johnson cash flow from operating activities for the quarter ending September 30, 2024 was $17.283B, a 15.78% increase year-over-year.
  • Johnson & Johnson cash flow from operating activities for the twelve months ending September 30, 2024 was $53.021B, a 13.25% increase year-over-year.
  • Johnson & Johnson annual cash flow from operating activities for 2023 was $22.791B, a 7.54% increase from 2022.
  • Johnson & Johnson annual cash flow from operating activities for 2022 was $21.194B, a 9.47% decline from 2021.
  • Johnson & Johnson annual cash flow from operating activities for 2021 was $23.41B, a 0.54% decline from 2020.
Johnson & Johnson Annual Cash Flow Ops
(Millions of US $)
2023 $22,791
2022 $21,194
2021 $23,410
2020 $23,536
2019 $23,416
2018 $22,201
2017 $21,056
2016 $18,767
2015 $19,569
2014 $18,710
2013 $17,414
2012 $15,396
2011 $14,298
2010 $16,385
2009 $16,571
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $351.152B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $755.342B 78.24
Novo Nordisk (NVO) Denmark $392.076B 28.27
AbbVie (ABBV) United States $318.085B 16.74
Merck (MRK) United States $251.572B 16.71
AstraZeneca (AZN) United Kingdom $205.572B 17.49
Novartis AG (NVS) Switzerland $201.027B 13.36
Pfizer (PFE) United States $151.535B 10.36
Sanofi (SNY) $122.552B 11.10
Bayer (BAYRY) Germany $19.138B 3.06
Innoviva (INVA) United States $1.113B 9.26